Baize Medical (02609.HK) Hot Stock Analysis and Risk Assessment

1. Company Overview
   : Baize Medical (02609.HK) is a Chinese oncology medical group operating 6 private for-profit hospitals and managing 2 non-profit hospitals. It provides full-cycle oncology medical services and drug/equipment supply, and was listed in June 2025 [4].
2. Price and Volume
   : As of December 2, 2025, the closing price was HK$5.41, a significant drop from the 52-week high of HK$19.88, and close to the 52-week low of HK$5.01 [0][3]. The day’s decline was 4.25%, with a trading volume of 4.6194 million shares, turnover rate of 0.35%, volume ratio of 1.86, and amplitude of 7.43% [0].
3. Fundamentals
   : The company is in a loss-making state, with a price-to-book ratio of 4.27, net asset per share of HK$1.27, and total market capitalization of HK$7.133 billion [0].
4. Market Sentiment and Capital Flow
   : There are 1,033 followers on the Xueqiu platform, with divided retail investor sentiment [2]; a net capital outflow of HK$4.6324 million occurred on November 27 [1].
5. Hot Stock Drivers
   : No clear catalysts have been found recently. It is speculated that the reasons for being on the list may include the overall popularity of the Hong Kong stock medical sector, investors’ continued attention to the oncology track, and bottom-fishing interest triggered by the stock price approaching its 52-week low [0].

• Hot stock logic is unclear
  : Although it made it to the East Money App Hot List, no major positive or negative news has been disclosed recently, and the stock price fluctuation may lack sustained driving factors.
• Valuation contradiction
  : The company maintains a price-to-book ratio of 4.27 despite losses, reflecting an overvalued state and adjustment risk [0].
• Price critical point
  : The current stock price is close to the 52-week low of HK$5.01. If it breaks below this support level, further selling may be triggered; if it breaks through the 50-day average price of HK$5.74, a short-term rebound is expected [0].

• Risks
  : Valuation risk (high price-to-book ratio + loss) [0]; Volatility risk (7.43% amplitude on the day, high uncertainty in short-term trends) [0]; Performance uncertainty (listed for less than half a year, lack of long-term public performance records) [0][4]; Lack of catalysts (no substantive news to drive it recently) [0].
• Opportunities
  : Long-term demand support for the oncology medical track [0]; The stock price approaching its 52-week low may attract bottom-fishing funds [0].

Baize Medical (02609.HK) is a Chinese oncology medical group listed in June 2025. Its current stock price is close to the 52-week low, with high recent volatility and no clear catalytic factors. The company is in loss, has a high price-to-book ratio, and market sentiment is divided. Attention should be paid to the support level of HK$5.01 and resistance levels of HK$5.74 (50-day average price) and HK$6.01 (100-day average price).

All data and analysis are based on public market information and internal databases, and do not include investment advice.